Ocular von Hippel-Lindau disease: Clinical update and emerging treatments

Current Opinion in Ophthalmology

Volumn 19, Issue 3, 2008, Pages 213-217

  Wong, Wai T ^a,b   Chew, Emily Y ^a  

^a NATIONAL EYE INSTITUTE   (United States)

^b Bldg 7 ^*  (United States)

Author keywords

Antiangiogenic therapy; Genotype phenotype correlations; Von Hippel Lindau disease

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; SEMAXANIB; SUNITINIB; VON HIPPEL LINDAU PROTEIN;

CRYOTHERAPY; DRUG EFFICACY; DRUG SAFETY; EYE SURGERY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEMANGIOBLASTOMA; HUMAN; LASER COAGULATION; PHENOTYPE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA TUMOR; REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; VON HIPPEL LINDAU DISEASE;

ANGIOGENESIS INHIBITORS; GENOTYPE; HEMANGIOMA, CAPILLARY; HUMANS; MUTATION; PHOTOCHEMOTHERAPY; PROGNOSIS; RETINAL NEOPLASMS; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 42149134812     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3282fb7c04     Document Type: Review

References (38)

1. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003; 361:2059-2067.
2. Singh AD, Shields CL, Shields JA. von Hippel-Lindau disease. Surv Ophthalmol 2001; 46:117-142.
3. Melmon KL, Rosen SW. Lindau's Disease: Review of the literature and study of a large kindred. Am J Med 1964; 36:595-617.
4. Kreusel KM, Bechrakis NE, Krause L, et al. Retinal angiomatosis in von Hippel-Lindau disease: a longitudinal ophthalmologic study. Ophthalmology 2006; 113:1418-1424. This retrospective study of 57 patients with ocular VHL disease with a mean followup of 7.3 years characterized the clinical course of retinal angiomatosis as one involving increasing tumor burden and decreasing visual acuity with time, underscoring the progressive nature of the disease.
5. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317-1320.
6. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998; 12:417-423.
7. Sgambati MT, Stolle C, Choyke PL, et al. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet 2000; 66:84-91.
8. Choyke PL, Glenn GM, Walther MM, et al. von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 1995; 196:582.
9. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-275.
10. Semenza GL. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999; 15:551-578.
11. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2:673-682.
12. Zbar B, Kishida T, Chen F, et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996; 8:348-357.
13. Beroud C, Joly D, Gallou C, et al. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res 1998; 26:256-258.
14. Czyzyk-Krzeska MF, Meller J. von Hippel-Lindau tumor suppressor: not only HIF's executioner. Trends Mol Med 2004; 10:146-149.
15. Rosenblatt MI, Azar DT. Antiangiogenic therapy: Prospects for treatment of ocular tumors. Semin Ophthalmol 2006; 21:151-160. This review summarizes recent investigations the state of knowledge and utilization of antiangiogenic therapies for ocular tumors, including uveal melanoma, retinoblastoma, metastatic disease, as well as ocular VHL disease.
16. Schlesinger T, Appukuttan B, Hwang T, et al. Internal en bloc resection and genetic analysis of retinal capillary hemangioblastoma. Arch Ophthalmol 2007; 125:1189-1193.
17. Garcia-Arumi J, Sararols LH, Cavero L, et al. Therapeutic options for capillary papillary hemangiomas. Ophthalmology 2000; 107:48-54.
18. Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology 2002; 109:1256-1266.
19. Wong WT, Agrón E, Coleman HR, et al. Clinical characterization of retinal capillary hemangioblastomas in a large population of patients with von Hippel-Lindau disease. Ophthalmology 2007; 30 May [Epub ahead of print]. This cross-sectional study involved a large number of clinically definite VHL patients collected using an unbiased ascertainment basis provides a quantitative and balanced profile of patients with ocular VHL disease in the terms of their clinical characteristics and the impact of VHL on ocular health.
20. Webster AR, Maher ER, Moore AT. Clinical characteristics of ocular angiomatosis in von Hippel-Lindau disease and correlation with germline mutation. Arch Ophthalmol 1999; 117:371-378.
21. Ong KR, Woodward ER, Killick P, et al. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 2007; 28:143-149. This large study compared the age-related risks of VHL disease manifestations before and after the advent of genetic testing and found an earlier and higher rate of disease detection in the eye and the kidney, attesting to the contribution in genetic testing. The study also analyzed a subset of patients with missense mutations and found that a truncated VHL protein product (from nonsense or frame-shift mutation) resulted in a higher age-related risk of kidney and eye disease when compared with mutations that deleted theVHL gene or resulted in a loss of protein structural integrity.
22. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995; 5:66-75.
23. Zbar B, Kishida T, Chen F, et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996; 8:348-357.
24. Neumann HP, Bender BU. Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med 1998; 243:541-545.
25. Sieving PA, Collins FS. Genetic ophthalmology and the era of clinical care. JAMA 2007; 297:733-736.
26. Blain D, Brooks BP. Molecular diagnosis and genetic counseling in ophthalmology. Arch Ophthalmol 2007; 125:196-203.
27. Wong WT, Agrón E, Coleman HR, et al. Genotype-phenotype correlation in von Hippel-Lindau disease with retinal angiomatosis. Arch Ophthalmol 2007; 125:239-245. In this large collection of patients, genotype-phenotype correlations between three classes of mutations (missense, protein-truncations, and deletions) and ocular phenotype were analyzed in terms of prevalence of ocular disease, ocular tumor characteristics, and visual outcome.
28. Dollfus H, Massin P, Taupin P, et al. Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci 2002; 43:3067-3074.
29. Stebbins CE, Kaelin WG Jr, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999; 284:455-461.
30. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427-434.
31. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25:4536-4541.
32. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
33. Aiello LP, George DJ, Cahill MT, et al. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology 2002; 109:1745-1751.
34. Girmens JF, Erginay A, Massin P, et al. Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas. Am J Ophthalmol 2003; 136:194-196.
35. Madhusudan S, Deplanque G, Braybrooke JP, et al. Antiangiogenic therapy for von Hippel-Lindau disease. JAMA 2004; 291:943-944.
36. von Buelow M, Pape S, Hoerauf H. Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma. Acta Ophthalmol Scand 2007; 85:114-116.
37. Ziemssen F, Voelker M, Inhoffen W, et al. Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. Eye 2007; 21:1125-1126. An interesting case report shows clear regression of retinal edema and tumor volume with local anti-VEGF treatment. The relative contributions of bevacizumab versus photodynamic therapy, however, were difficult to discern.
38. Dahr SS, Cusick M, Rodriguez-Coleman H, et al. Intravitreal antivascular endothelial growth factor therapy with pegaptanib for advanced von Hippel-Lindau disease of the retina. Retina 2007; 27:150-158. This investigation provides an example of the kind of prospective pilot study useful in preliminary investigations of new therapies. The development of an applicable animal model of ocular VHL will further facilitate the discovery of effective therapeutic approaches.